Lv41
618 积分 2023-11-24 加入
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
7小时前
已完结
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
25天前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
2个月前
已完结
SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
5个月前
已完结
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
6个月前
已完结
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
6个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
6个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
6个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
7个月前
已完结
皖公网安备34019202002308
